Global Companion Animal Diagnostics Market Outlook
Revenue, 2024
$3.3B
Forecast, 2034
$7.8B
CAGR, 2025 - 2034
8.9%
The Companion Animal Diagnostics industry revenue is expected to be around $3.6 billion in 2025 and expected to showcase growth with 8.9% CAGR between 2025 and 2034. I notice that companion animal diagnostics is becoming central to veterinary care. Rising pet ownership, growing awareness of animal health and the humanization of pets drive this change. Veterinary hospitals and clinics with diagnostic laboratories make up 75.7% of end user demand and the data shows the critical role of advanced veterinary diagnostic tests, in routine screening, disease management and pre surgical assessment. The dominance of consumables, which generated $2.12 billion in revenue in 2024, highlights the recurring, procedure based nature of the veterinary diagnostics market, as practices rely on reagents, assay kits, and cartridges to support high testing volumes and rapid clinical decision making.
The field of companion animal diagnostics uses various technologies including clinical chemistry and hematology and immunodiagnostics and molecular diagnostic assays and diagnostic imaging to provide fast and accurate information about animal health and disease. The tools enable veterinarians to perform essential tests for pet disease detection and chronic condition management and pre anesthetic assessments and cancer diagnosis for dogs and cats. The veterinary diagnostics market shows increasing demand for automated in clinic analyzers which provide immediate results while advanced veterinary laboratories perform specialized tests including genomics and antimicrobial resistance profiling. The veterinary field has experienced changes in clinical operations because of new point of care testing systems that link with practice management software and remote interpretation services and data based wellness platforms. Companion animal diagnostics continues to play an essential role in veterinary practice because of its evidence based approach.
Market Key Insights
The Companion Animal Diagnostics market is projected to grow from $3.3 billion in 2024 to $7.8 billion in 2034. This represents a CAGR of 8.9%, reflecting rising demand across Clinical Pathology, Veterinary Bacteriology, and Veterinary Virology.
IDEXX, Zoetis Services, and Mars Incorporated are among the leading players in this market, shaping its competitive landscape.
The Companion Animal Diagnostics market shows the United States and Germany as its leading markets which will experience CAGR growth rates of 6.5% to 9.3% during 2024 to 2030.
The market research predicts that India, Brazil and Mexico will experience the highest growth rates at 8.5% to 11.1% CAGR.
Transition like Shift Toward Preventive Care is expected to add $585 million to the Companion Animal Diagnostics market growth by 2030
.The Companion Animal Diagnostics market is set to add $4.5 billion between 2024 and 2034, with manufacturer targeting Bacteriology & Virology Application projected to gain a larger market share.
With
rising-humanization of pets and expanding preventive care programs accelerating advanced companion animal diagnostics adoption, and
Rapid adoption of point-of-care veterinary testing improving turnaround times and clinical outcomes in companion diagnostics, Companion Animal Diagnostics market to expand 135% between 2024 and 2034.
Opportunities in the Companion Animal Diagnostics
The veterinary diagnostics market now faces pressure from urban pet owners who want immediate test results during their clinic visits. The veterinary reference laboratory sector serves as the primary laboratory testing destination for independent small animal practices that perform most of their lab work. The global market for cartridges and reagents and immunoassay test kits reached 2.12 billion in 2024 and will also expand to 3.69 billion by 2030 while instruments will grow from 1.20 to 1.84 billion so North America and Europe will see the highest growth in inclinic analyzer consumables.
Growth Opportunities in North America and Europe
The North American companion animal diagnostics market operates under high pet healthcare spending and established payment systems which make veterinary hospitals and clinics the dominant end users but reference diagnostic laboratories gain importance through their complex testing capabilities including molecular diagnostics and advanced immunoassays. The market offers three main opportunities which include the development of connected in clinic analyzers and point of care testing for chronic disease monitoring and the integration of digital pathology with practice management systems and flexible service models for corporate clinic chains and specialty oncology and cardiology centers. The market competition between multinational leaders and regional veterinary diagnostics providers intensifies because they compete through fast testing times and teleconsultation services and preventive care package offerings which drives manufacturers to develop workflow automation systems and AI based image analysis tools and practitioner training programs to enhance clinic level adoption. The market experiences growing demand because more pets get insurance coverage and owners choose human grade diagnostic standards for their dogs and cats while wellness plans gain popularity which leads to increased testing rates and higher prices for advanced companion animal diagnostic solutions.
The European market for companion animal diagnostics faces strong regulatory control because of standardized quality requirements and numerous national and regional diagnostic laboratories which serve as primary users for extensive testing needs. The main users of high volume testing at veterinary hospitals and specialty clinics perform acute care and select high value in house assays. The market presents three main business opportunities which include laboratory consolidation between countries and the creation of disease specific panels for zoonotic and vector borne diseases and the implementation of multi market compliant in clinic analyzers. The market competition involves established worldwide brands which work against cooperative and university based laboratories to create partnerships for developing new tests and sharing data and providing training services and obtaining licenses to speed up molecular diagnostic and clinical chemistry platform deployments. The main factors driving the market in different regions include increasing pet ownership in cities and ongoing veterinary preventive care funding and public understanding of One Health principles which support integrated diagnostic systems that connect primary care facilities with specialty clinics and central laboratories through digital pathology networks.
Market Dynamics and Supply Chain
01
Driver: Rising humanization of pets and expanding preventive care programs accelerating advanced companion animal diagnostics adoption
Pet owners now require hospital level medical care which leads to higher demand for complete diagnostic tests for all animal species at different life stages. Veterinary clinics and corporate hospitals and wellness centers now implement preventive care programs which lead to regular blood chemistry tests and serology and fecal examinations. The increasing practice of annual wellness panels for dogs and cats and exotic pets leads to higher recurring revenue for veterinary diagnostic companies. The combination of in clinic analyzers with cloud based laboratory information systems allows for fast screening tests which support individualized medical care and extended disease management plans. The expansion of pet insurance coverage and wellness plans makes diagnostic tests more accessible which leads owners to perform imaging and molecular tests on healthy pets. The veterinary profession now focuses on continuous health monitoring instead of treating illnesses episodically which also creates higher demand for diagnostic panels that monitor organ function and endocrine system and inflammatory biomarkers. The fundamental changes in the healthcare system have also established companion animal diagnostics as an essential component of contemporary preventive pet medical care.
Point of care testing has also become widely accepted in veterinary diagnostics because it changes both veterinary clinical operations and what pet owners expect from their veterinarians. The combination of portable analyzers with integrated hematology and chemistry platforms and cartridge based immunoassays produces fast results which enable veterinarians to make decisions during the same visit. The fast result times from point of care testing enable veterinarians to practice evidence based medicine while improving antimicrobial treatment and emergency and critical care patient assessment. The cloud based system enables automatic result transfer to practice management systems which simplifies record management and enables specialists to provide telemedicine services through remote consultations. Veterinary clinics now purchase point of care diagnostic systems because they want to offer unique services while generating laboratory revenue and delivering better patient care.
02
Restraint: High diagnostic procedure costs and limited pet insurance coverage suppress routine testing adoption and volumes
The high cost of advanced companion animal diagnostic equipment including in clinic analyzers and imaging devices prevents price conscious pet owners from getting their pets tested even when veterinarians recommend it because few pets have insurance coverage which results in decreased diagnostic testing and reduced veterinary clinic revenue and slower market expansion in veterinary diagnostics.
03
Opportunity: Advanced molecular and genetic companion animal diagnostics for oncology focused veterinary centers throughout Japan and Affordable preventive companion animal diagnostics for middle class pet owners in India, Brazil, and Southeast Asia
The aging pet population in Japan along with its high pet insurance coverage rates create market demand for veterinary diagnostic tests which operate similarly to human cancer diagnosis systems. Medical facilities that perform diagnostics on pets now want to use molecular profiling and liquid biopsy and PCR based pathogen panels but these tests remain scarce in Japan because of payment restrictions. The diagnostic market for companion animals in Japan will become accessible through partnerships between diagnostic companies and academic institutions and specialty veterinary networks. The Japanese market shows higher growth potential for molecular and genetic testing instruments than for consumables and routine chemistry assays.
The growing number of pet owners in India Brazil and Southeast Asia faces challenges because they lack access to high quality diagnostic services for companion animals in non urban areas. The market requires affordable diagnostic solutions which include vector borne and parasitic disease screening and basic biochemistry tests and wellness profiles for owners who want affordable options and small clinics. The introduction of affordable consumables through local distributors and corporate clinic chains will enable companies to reach more customers. The emerging markets will experience the highest growth rate from their large production of standard infectious disease and preventive testing consumables.
04
Challenge: Shortage of skilled veterinary professionals constrains advanced test utilization and delays practice investment in diagnostics
The shortage of trained veterinarians and technicians limits the implementation of advanced veterinary diagnostic methods including molecular assays and point of care testing platforms which forces practices to focus on fundamental services instead of advanced diagnostic processes. The limited capacity creates delays in test results and prevents practices from adopting new diagnostic technologies which restricts market growth despite rising pet healthcare needs.
Supply Chain Landscape
1
Molecular Diagnostics Inputs
INDICAL BIOSCIENCE GmbHZoetis Services LLCVirbac
2
Animal Diagnostics
IDEXXZoetis Services LLCVirbac
3
Veterinary Diagnostics
IDEXXMars IncorporatedZoetis Services LLC
4
Pet Health
veterinary clinicsdiagnostic reference laboratoriesacademic research institutes
1
Molecular Diagnostics Inputs
INDICAL BIOSCIENCE GmbHZoetis Services LLCVirbac
2
Animal Diagnostics
IDEXXZoetis Services LLCVirbac
3
Veterinary Diagnostics
IDEXXMars IncorporatedZoetis Services LLC
4
Pet Health
veterinary clinicsdiagnostic reference laboratoriesacademic research institutes
Use Cases of Companion Animal Diagnostics in Clinical Pathology & Veterinary Bacteriology
Clinical Pathology : The practice of clinical pathology serves as the fundamental diagnostic tool for companion animals because it enables both basic health checks and advanced disease treatment in veterinary clinics. The diagnostic laboratory sector generates most of its USD 1.04 billion revenue from 2024 through 2030 at a 9.1% annual growth rate while veterinary hospitals and clinics generate USD 1.48 billion at an 8.3% annual growth rate. The clinical pathology process depends on in clinic analyzers for hematology and biochemistry tests which operate with immunoassays and urinalysis systems while requiring continuous reagent and slide and control purchases to maintain 63.85% of total product demand for consumables in companion animal diagnostics. IDEXX maintains its market leadership through its complete analyzer systems and wide reference laboratory network which provides complete testing options and strong data analysis capabilities that deeply integrate with veterinary practice operations. The clinical pathology market receives support from Zoetis Services LLC and Mars Incorporated through their wide reference laboratory services and clinical consulting expertise while Virbac uses its therapeutic and preventive products and INDICAL BIOSCIENCE GmbH adds advanced molecular workflow elements for complex small animal cases.
Veterinary Bacteriology : Bacteriology is a key component of pet testing, identifying the causes of skin, respiratory, gastrointestinal, and urinary problems in companion animals. It enables veterinarians to select antibiotics based on evidence and apply responsible antimicrobial stewardship. Diagnostic laboratories generated USD 1.04 billion in revenue in 2024, while specialty clinics earned about USD 0.49 billion. Both diagnostic laboratories and specialty clinics make extensive use of bacteriology testing. Bacteriology testing for laboratories is projected to grow at a 9.1% CAGR, while specialty clinics are expected to grow at about 9.4% annually through 2030, driven by the rising incidence of complex infections. End users routinely apply culture and antibiotic susceptibility testing alongside PCR assays to accelerate pathogen identification and resistance profiling, ensuring therapeutic decisions align with clinical guidelines. Bacteriology represents a high consumable use segment within companion animal diagnostics, with culture media, identification panels, and susceptibility discs used daily, generating recurring revenue for suppliers. IDEXX and Mars Incorporated, supported by extensive reference laboratory infrastructures, deliver comprehensive bacteriology panels with rapid turnaround and integrated reporting to support clinical decision making. INDICAL BIOSCIENCE GmbH has established a strong niche with standardized molecular solutions for high consequence and fastidious bacterial pathogens. Zoetis Services LLC and Virbac leverage their anti infective and vaccine portfolios to link bacteriological insights with optimized treatment and prevention strategies, strengthening their role as full service partners to veterinarians managing infectious diseases in companion animals.
Veterinary Virology : The field of virology has become a vital strategic use for companion animal diagnostics because it helps identify and control major viral diseases that affect dogs and cats including parvovirus and feline leukemia virus and dangerous respiratory viruses which lead to quick progression when symptoms are not only detected early. The veterinary hospital and clinic sector which brought in USD 1.48 billion during 2024 expects 8.3% annual growth until 2030 for their revenue. The diagnostic process at veterinary hospitals and clinics depends on fast test kits and serologic panels for immediate results but laboratories conduct molecular tests for complex cases and surveillance of regional outbreaks. The increasing number of pet owners who practice preventive health care for their pets has created higher demand for virology based companion animal diagnostic tests which help with vaccination screening and pre boarding checks and early life health assessments. Point of care testing serves as a critical tool for veterinarians to identify infectious animals quickly while creating customized vaccination plans and delivering specific risk information to owners which results in better medical results and higher client contentment. The veterinary virology market leaders IDEXX and Zoetis Services LLC maintain their market dominance through their wide range of dependable point of care testing solutions and complete reference lab services which provide fast and easy to read results for small animal diagnostics. Mars Incorporated maintains its market presence through complete virology testing options and expert advisory services at its laboratory facilities while INDICAL BIOSCIENCE GmbH provides advanced molecular virology solutions to sophisticated laboratories and reference centers and Virbac uses its extensive vaccine and antiviral range to connect laboratory based diagnosis to individualized preventive and treatment plans thus strengthening its position in this expanding diagnostic market.
Recent Developments
The companion animal diagnostic field advances through two main developments which include point of care testing and veterinary imaging technologies that enhance both speed and accuracy of medical choices. The combination of pet humanization trends and rising veterinary expenses leads to increased market demand for molecular diagnostics and immunoassays and digital pathology solutions in small animal healthcare. The veterinary diagnostic market experiences a major shift because AI powered diagnostic systems and telemedicine services now allow veterinarians to monitor patients remotely while using predictive analytics for better treatment plans.
August 2023 : Mars Incorporated acquired Heska Corporation to expand its Antech veterinary diagnostics business through the acquisition of Heska Corporation which specializes in companion animal diagnostics equipment and point of care testing systems.
July 2022 : Zoetis Services LLC purchased Basepaws which operates as a pet genomics and at home health testing company to expand its companion animal diagnostics portfolio through DNA based screening technology which helps veterinarians provide individualized preventive care and data based treatment choices for small animals.
Impact of Industry Transitions on the Companion Animal Diagnostics Market
As a core segment of the Medical Device industry,
the Companion Animal Diagnostics market develops in line with broader industry shifts.
Over recent years, transitions such as Shift Toward Preventive Care and Rise of Advanced Technologies have redefined priorities
across the Medical Device sector,
influencing how the Companion Animal Diagnostics market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Shift Toward Preventive Care
The Companion Animal Diagnostics market is undergoing a significant transition towards preventive care, driven by advancements in data driven health monitoring systems. This evolution from sporadic testing to continuous health assessments, facilitated by in clinic analyzers, point of care testing, and connected wearables, empowers veterinarians to identify chronic diseases early, thereby enhancing treatment strategies. This shift not only transforms diagnostic approaches but also introduces innovative risk assessment models for pet insurance, supports adherence to medication plans, and increases telemedicine consultations. As a result, the market is projected to grow by $549 million by 2030, underscoring the strategic importance of real time diagnostic information in creating differentiated services for retail pet wellness programs and corporate veterinary chains, ultimately generating sustainable revenue streams. This industry transition is expected to add $585 million in the industry revenue between 2024 and 2030.
02
Rise of Advanced Technologies
The second major shift in the industry occurs through technology intensification because companion animal diagnostics now use molecular diagnostics and advanced biomarker panels. The combination of high throughput analyzers with imaging systems and digital pathology platforms enables faster study completion and better veterinary clinical choices. The transition enables better collaboration between veterinary and human diagnostic and pharmaceutical industries because they work together to develop shared assays and establish common quality standards and use disease models that span multiple species. Contract research organizations and specialty reference laboratories expand their services to convert complex data into practical evidence which enables successful regulatory approvals and precise dosing methods and improved animal health product development.